| Literature DB >> 24984844 |
Andrew J Neal1, Bruce C V Campbell2, Arvind Chandratheva2, Peter J Hand2, Stephen M Davis2.
Abstract
The risk of thrombolysis in patients taking novel anticoagulants remains unclear. We describe a patient with a large acute ischaemic stroke, who had a low calibrated anti-factor Xa level, who safely received thrombolysis 15-17 hours after standard dose rivaroxaban without subsequent intracerebral haemorrhage.Entities:
Keywords: Rivaroxaban; Stroke; Thrombolysis; Thrombolytic therapy
Mesh：
Substances：
Year: 2014 PMID： 24984844 DOI： 10.1016/j.jocn.2014.03.029
Source DB: PubMed Journal: J Clin Neurosci ISSN： 0967-5868 Impact factor: 1.961